Wyeth's 'A3/Prime-2' ratings for possible upgrade - Moody's (Sharewatch)
LONDON (Thomson Financial) - Moody's Investors Service said it has placed the ratings of Wyeth, rated 'A3 long term, Prime-2 short term' under review for possible upgrade, following two new FDA approvals and the recent resolution of FDA manufacturing compliance issues.

FDA slaps MedImmune with FluMist warning letter (CNN Money)
The FDA slapped MedImmune with a warning letter over manufacturing problems with its product FluMist, and barred the company from any further approvals for the vaccine until the problems are resolved.